Conrad, N. et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401, 1878–1890 (2023).

Article  PubMed  Google Scholar 

Agrawal, M. et al. Changing epidemiology of immune-mediated inflammatory diseases in immigrants: a systematic review of population-based studies. J. Autoimmun. 105, 102303 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Conrad, N. et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 400, 733–743 (2022).

Article  PubMed  Google Scholar 

Tyndall, A. J. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 69, 1809–1815 (2010).

Article  PubMed  Google Scholar 

Libby, P. & Weyand, C. Immune and inflammatory mechanisms mediate cardiovascular diseases from head to toe. Cardiovasc. Res. 117, 2503–2505 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Tschöpe, C., Cooper, L. T., Torre-Amione, G. & Van Linthout, S. Management of myocarditis-related cardiomyopathy in adults. Circ. Res. 124, 1568–1583 (2019).

Article  PubMed  Google Scholar 

Goodson, N. J. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 52, 2293–2299 (2005).

Article  CAS  PubMed  Google Scholar 

Solomon, D. H. et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 67, 1449–1455 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arts, E. E. A., Fransen, J., Den Broeder, A. A., Van Riel, P. L. C. M. & Popa, C. D. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann. Rheum. Dis. 76, 1693–1699 (2017).

Article  CAS  PubMed  Google Scholar 

Myasoedova, E. et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann. Rheum. Dis. 75, 560–565 (2016).

Article  CAS  PubMed  Google Scholar 

Provan, S. A. et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann. Rheum. Dis. 70, 812–817 (2011).

Article  PubMed  Google Scholar 

Crowson, C. S. et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann. Rheum. Dis. 77, 48–54 (2018).

Article  CAS  PubMed  Google Scholar 

Roy, P., Orecchioni, M. & Ley, K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat. Rev. Immunol. 22, 251–265 (2022).

Article  CAS  PubMed  Google Scholar 

Mallat, Z. & Binder, C. J. The why and how of adaptive immune responses in ischemic cardiovascular disease. Nat. Cardiovasc. Res. 1, 431–444 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Panahi, M. et al. Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. Cardiovasc. Res. 114, 1445–1461 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarwar, N. et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012).

Article  PubMed  Google Scholar 

IL6R MR Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 379, 1214–1224 (2012).

Article  Google Scholar 

Weber, B. N., Giles, J. T. & Liao, K. P. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nat. Rev. Rheumatol. 19, 417–428 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Choy, E. H. et al. Translating IL-6 biology into effective treatments. Nat. Rev. Rheumatol. 16, 335–345 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).

Article  CAS  PubMed  Google Scholar 

Akita, K., Isoda, K., Sato-okabayashi, Y., Kadoguchi, T. & Kitamura, K. An interleukin-6 receptor antibody suppresses atherosclerosis in atherogenic mice. Front. Cardiovasc. Med. 4, 84 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Cai, T. et al. Association of interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy a phenome-wide association study. JAMA Cardiol. 3, 849–857 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060–2069 (2021).

Article  CAS  PubMed  Google Scholar 

Brock, K. et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 77, 1845–1855 (2021).

Article  Google Scholar 

Ridker, P. M. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc. Res. 117, e138–e140 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Del Buono, M. G. et al. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: a focus on Interleukin-1. Eur. J. Clin. Invest. 54, e14110 (2024).

Article  PubMed  Google Scholar 

Broderick, L. & Hoffman, H. M. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat. Rev. Rheumatol. 18, 448–463 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schiff, M. H. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann. Rheum. Dis. 59, 103–108 (2000).

Article  Google Scholar 

Abbate, A. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117, 2670–2683 (2008).

Article  CAS  PubMed  Google Scholar 

Abbate, A. et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment–elevation myocardial infarction. J. Am. Heart Assoc. 9, e014941 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abbate, A. et al. Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur. Heart J. Cardiovasc. Pharmacother. 8, 503–510 (2022).

Article  PubMed  Google Scholar 

Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

Article  CAS  PubMed